Astellas, Vir Biotechnology Form Global Collaboration to Advance VIR-5500 Prostate Cancer Program

Astellas Pharma Inc. (TSE: 4503) and Vir Biotechnology, Inc. (Nasdaq: VIR) have entered a global strategic collaboration to co-develop and co-commercialize VIR-5500, a PSMA-targeting PRO-XTEN dual-masked T-cell engager for the treatment of prostate cancer. Under the agreement, the two companies will share development expenses and revenues, with Astellas leading commercialization in the United States and obtaining exclusive commercial rights outside the U.S. Vir Biotechnology retains an option to co-promote VIR-5500 in the U.S. market.

Financial terms, including any upfront payment, milestone structure, or profit-share ratio, were not disclosed in the available announcement materials.

Deal Structure and Territorial Rights

The Astellas Vir Biotechnology collaboration is structured as a co-development and co-commercialization partnership rather than a conventional out-licensing arrangement. Both parties will share expenses and revenues associated with VIR-5500 clinical development and, if the program reaches the market, commercialization.

Astellas will serve as the lead commercial party in the United States, the largest single market for oncology therapeutics. Vir Biotechnology retains an option to co-promote in the U.S., preserving a degree of commercial participation in its home market. Outside the United States, Astellas will hold exclusive rights, giving the Tokyo-based company global commercial control across Europe, Asia, and the rest of the world.

The deal does not appear to encompass Vir's broader PRO-XTEN platform or additional undisclosed targets. Based on the available information, the collaboration is focused on VIR-5500 as a single clinical-stage asset.

VIR-5500: A PSMA T-Cell Engager With Conditional Activation

VIR-5500 is a bispecific T-cell engager that simultaneously binds PSMA (prostate-specific membrane antigen) on tumor cells and CD3 on T cells, redirecting cytotoxic T-cell activity toward PSMA-expressing cancer cells. The molecule is built on Vir Biotechnology's proprietary PRO-XTEN platform, which incorporates two masking domains — large, inert polypeptide shields — that block the active binding arms of the bispecific while it circulates systemically.

These masks are designed to be cleaved by proteases enriched in the tumor microenvironment. In theory, this dual-masking mechanism keeps VIR-5500 inactive in healthy tissues and the bloodstream, activating the molecule selectively at the tumor site. The XTEN component also extends the molecule's half-life, potentially enabling less frequent dosing compared to conventional T-cell engager formats.

The core problem the PRO-XTEN dual-masked design addresses is the therapeutic-index limitation that has constrained T-cell engagers in solid tumors. PSMA is expressed not only on prostate cancer cells but also at lower levels on normal tissues including salivary glands, lacrimal glands, and the small intestine. Conventional, unmasked PSMA-directed T-cell engagers activate T cells wherever PSMA is present, leading to on-target, off-tumor toxicity and systemic cytokine release syndrome (CRS). These dose-limiting toxicities have been a recurring challenge across the class.

VIR-5500 Clinical Development Status

VIR-5500 (also designated AMX-500 and SAR446329) is in Phase 1 clinical testing. A recruiting, multi-part first-in-human study is evaluating the safety, pharmacokinetics, and preliminary efficacy of VIR-5500 in patients with hormone-refractory prostate cancer. The trial has an enrollment target of up to 390 subjects, with a study start date of August 2023 and an estimated completion date of September 2027.

The Phase 1 protocol includes combination arms with enzalutamide and darolutamide, two androgen receptor signaling inhibitors already approved for prostate cancer. Primary endpoints include the incidence of treatment-emergent adverse events in dose-escalation parts and objective response rate in expansion cohorts. Trial sites span multiple regions, including the United Kingdom, Spain, Australia, the United States, and South Korea.

No clinical data from the Phase 1 program have been publicly disclosed at the time of this announcement.

Strategic Rationale for Astellas

Astellas has a deep commercial footprint in prostate cancer through XTANDI (enzalutamide), which it originally co-developed and co-commercialized with Pfizer (and previously with Medivation before Pfizer's acquisition of that company). XTANDI has generated tens of billions of dollars in cumulative global revenue and remains a standard-of-care androgen receptor inhibitor across multiple prostate cancer settings.

The addition of VIR-5500 would give Astellas a mechanistically distinct asset in its prostate cancer franchise — one that operates through immune-mediated cytotoxicity rather than androgen receptor blockade. The inclusion of enzalutamide as a combination partner in the VIR-5500 Phase 1 trial underscores the potential for intra-portfolio synergy. A prostate cancer treatment bispecific that could be layered onto or sequenced with existing hormonal therapies would extend Astellas's competitive position in a disease area where it already has commercial infrastructure, key opinion leader relationships, and payer access.

Competitive Landscape for PSMA-Directed T-Cell Engagers

VIR-5500 enters a competitive and increasingly crowded field. Amgen's xaluritamig, a half-life-extended BiTE targeting PSMA and CD3, is the most clinically advanced program in the class, having progressed to Phase 3 in metastatic castration-resistant prostate cancer. Phase 1 data for xaluritamig showed PSA50 responses in approximately 30% of heavily pretreated patients, but CRS and salivary gland toxicity were observed, consistent with the class-wide therapeutic-index challenge.

Johnson & Johnson is developing JNJ-081, a PSMA-directed CD3 bispecific in the DuoBody format, in Phase 1. Merck acquired Harpoon Therapeutics and its PSMA-targeting TriTAC program HPN424 in 2024. Regeneron is pursuing a differentiated dual-bispecific strategy combining REGN4336 (PSMA × CD3) with REGN5668 (PSMA × CD28 costimulatory bispecific) to enhance T-cell activation while potentially mitigating toxicity. AbbVie acquired TeneoTwo and its PSMA × CD3 asset TNB-585 in 2022.

Beyond bispecifics, PSMA-directed cellular therapies are also in development. Roche acquired Poseida Therapeutics and its PSMA CAR-T program P-PSMA-101 in 2024. Bellicum Pharmaceuticals is testing BPX-601, a PSMA-directed GoCAR-T with a drug-controllable activation switch.

The approved PSMA-targeted therapy that defines the current standard is Novartis's Pluvicto (lutetium Lu-177 vipivotide tetraxetan), a radioligand therapy approved by the FDA in 2022 for PSMA-positive metastatic castration-resistant prostate cancer after prior treatment with an androgen receptor pathway inhibitor and taxane-based chemotherapy. Any new PSMA-directed agent, including VIR-5500, will need to define its clinical positioning relative to Pluvicto — whether in combination, in radioligand-refractory patients, or in earlier treatment lines.

The pattern of large-pharma acquisitions and partnerships across the PSMA × CD3 space — Merck, Roche, AbbVie, and now Astellas — reflects sustained strategic conviction that redirected T-cell approaches can address unmet need in advanced prostate cancer, despite the toxicity challenges that have limited the class to date.

What This Deal Signals

The Astellas Vir Biotechnology collaboration represents a bet that conditional activation technology can differentiate VIR-5500 from the growing roster of conventional PSMA T-cell engagers. The dual-masking mechanism of the PRO-XTEN platform is designed to address the specific safety liabilities — CRS, salivary gland damage, and other on-target/off-tumor effects — that have constrained competitors in clinical testing. Whether this translates into a wider therapeutic window and a viable clinical profile will depend on data from the ongoing Phase 1 program, which is not expected to complete until 2027.

For Vir Biotechnology, the deal provides a development and commercialization partner with an established prostate cancer franchise and global commercial infrastructure. For Astellas, it adds a next-generation, immune-based mechanism to a portfolio historically anchored in androgen receptor inhibition, at a time when the treatment landscape for advanced prostate cancer continues to expand in complexity.

---

Spot something wrong? Report an issue with this article